MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN AUSTRALIA AND NEW ZEELAND

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN AUSTRALIA AND NEW ZEELAND

Moberg Derma AB (publ.) has entered into a distribution agreement with
OzHealth Pharma for Emtrix® - for discolored and damaged nails caused by
nail fungus (onychomycosis) or nail psoriasis. Under the agreement OZ
Pharma Health is granted exclusive rights to market and sell Emtrix® in
Australia and New Zeeland.

”The agreement is part of our international commercialization of
Emtrix®, which now will be marketed in another large market. We
currently have secured distributors for Emtrix® in over 20 markets,”
comments Moberg Derma's CEO, Peter Wolpert.

About Emtrix® and nail diseases Emtrix® is a prescription free, topical
nail product and has the potential to become first-line treatment for
common nail disorders. Launch of Emtrix® was initiated in the first
markets in September 2010. Safety and efficacy have been demonstrated in
several clinical studies including more than 500 patients. Emtrix® has a
unique and rapid mechanism of action which brings visible improvements
within 2-4 weeks of treatment. Nail fungus is the most common nail
disease and afflicts approximately 10% of the general population and
increasing with age. The estimated global market potential exceeds USD 1
billion. The untapped potential is significant since many patients
remain untreated. It is generally recognized that there is a need for
new efficacious and safe topical treatments.

For further information, please contact:
Peter Wolpert, President and CEO of Moberg Derma Telephone: +46 8 522
307 00 Mobile: +46 735 71 35 E-mail:
peter.wolpert@mobergderma.se (peter.wolpert@mobergderma.se)
Magnus Persson, IR Mobile: +46 73-355 26 01 E-mail:
magnus.persson@mobergderma.se (magnus.persson@mobergderma.se)

Moberg Derma discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication on 8 June, 08:00 am.